RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that ...
Source: Johnson and Johnson - May 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Corticosteroid Bursts May Increase GI Bleeding Risk in Children Corticosteroid Bursts May Increase GI Bleeding Risk in Children
Oral corticosteroid bursts are associated with an increased risk of gastrointestinal bleeding, sepsis, and pneumonia during the month after treatment initiation, according to a cohort study in Taiwan.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - May 5, 2021 Category: Emergency Medicine Tags: Pediatrics News Source Type: news
Topical Corticosteroid Use in Pregnancy Not Tied to SGA, LBW
WEDNESDAY, May 5, 2021 -- Topical corticosteroid use in pregnancy is not associated with increased risks for small for gestational age (SGA) or low birth weight, according to a study published online May 5 in JAMA Dermatology.
Niklas Worm... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 5, 2021 Category: Pharmaceuticals Source Type: news
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, The Lancet
In patients with hypoxia and evidence of systemic inflammation (C-reactive protein ≥75 mg/L), the addition of tocilizumab to usual standard of care (82% receiving systemic corticosteroids) reduced 28-day mortality (31% v 35%; rate ratio 0.85; 95% CI 0.76–0.94; p=0.0028). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 4, 2021 Category: Consumer Health News Source Type: news
Featured Review: Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma
New Cochrane Review on the efficacy and safety of inhalers for those with mild asthma published on World Asthma Day.World Asthma Day on 5 May is an annual event on organized by the Global Initiative for Asthma (GINA) to improve asthma awareness and care around the world.Cochrane Airways works with authors (typically clinicians and researchers) to produce systematic reviews on chronic obstructive pulmonary disease (COPD), bronchiectasis and other lung diseases, and asthma. We asked Dr Timothy Hinks, one of the Cochrane Review authors, about the findings of this recent review.For those with mild asthma, there are differ...
Source: Cochrane News and Events - April 29, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context, The Lancet Respiratory Medicine
Article reviews clinical& methodological heterogeneity of studies of IL-6 antagonists,& considers how this might have influenced reported treatment effects. Severity of illness and concomitant corticosteroids are among factors that might have contributed to inconsistent results (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 29, 2021 Category: Consumer Health News Source Type: news
Horizontal transmission can cause severe and persistent eye inflammation
This study highlights a novel mode of transmission for HTLV-1 uveitis. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 27, 2021 Category: Infectious Diseases Source Type: news
Separate Corticosteroid Injections From COVID Vaccine by 2 Weeks Separate Corticosteroid Injections From COVID Vaccine by 2 Weeks
Clinicians may still want to time elective corticosteroid injections at least two weeks before or after receipt of this vaccine, according to a group of doctors writing on behalf of the Spine Intervention Society.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - April 26, 2021 Category: Orthopaedics Tags: Infectious Diseases News Source Type: news
Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); however, combination...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
COVID-19 rapid guideline: managing COVID-19 [NG191], NICE (updated 8th April 2021)
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together existing recommendations on managing COVID-19 so that healthcare staff and those planning and delivering services can find and use them more easily. The guideline includes new recommendations on therapeutics, and we will update the guideline further as new evidence emerges.
8 April 2021, Recommendations for using corticosteroids, tocilizumab and sarilumab to treat COVID-19 were added (including the evidence and rationale for making the recommendations). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 15, 2021 Category: Consumer Health News Source Type: news
Topical Dermatologic Corticosteroids: in Vivo Bioequivalence
Biopharmaceutics (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 13, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Common asthma drug speeds up COVID-19 recovery in high-risk patients
A common corticosteroid shortens COVID-19 recovery times for patients aged over 50 who are at high risk of developing severe illness, a groundbreaking GP-led trial has found. (Source: GP Online News)
Source: GP Online News - April 12, 2021 Category: Primary Care Tags: Coronavirus Source Type: news
Common asthma drug speeds up COVID-19 recovery in community for high-risk patients
A common corticosteroid shortens COVID-19 recovery times for patients aged over 50 who are at high risk of developing severe illness, a groundbreaking GP-led trial has found. (Source: GP Online News)
Source: GP Online News - April 12, 2021 Category: Primary Care Tags: Coronavirus Source Type: news
Sobrin Receives Research to Prevent Blindness Physician-Scientist Award
Lucia Sobrin, MD, MPH, of the Division of Ophthalmology, won the Physician-Scientist Award from Research to Prevent Blindness (RPB) for her work in identifying genes that influence the risk of developing ocular hypertension after corticosteroid use. (Source: BWH News)
Source: BWH News - March 29, 2021 Category: Hospital Management Source Type: news
Remdesivir and clinical improvement in hospitalized patients with COVID-19
(JAMA Network) This comparative effectiveness research study that included a high proportion of non-White individuals assesses whether remdesivir administered alone or with corticosteroids is associated with time to clinical improvement or time to death in patients hospitalized with confirmed COVID-19. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 24, 2021 Category: International Medicine & Public Health Source Type: news
